Medicine & Life Sciences
Cholangiocarcinoma
100%
Pancreatic Neoplasms
70%
Survival
69%
Neoplasms
59%
Fibroblast Growth Factor Receptors
46%
Therapeutics
44%
Adenocarcinoma
41%
Hepatocellular Carcinoma
39%
Biliary Tract Neoplasms
37%
Drug Therapy
36%
Progression-Free Survival
33%
selinexor
31%
gemcitabine
29%
Immunotherapy
27%
Receptor, Fibroblast Growth Factor, Type 2
26%
trifluridine tipiracil
23%
Gallbladder Neoplasms
23%
Colorectal Neoplasms
23%
Sorafenib
21%
Safety
19%
Nivolumab
19%
Clinical Trials
18%
Neoadjuvant Therapy
18%
Cell Nucleus Active Transport
17%
Squamous Cell Carcinoma
16%
pembrolizumab
16%
atezolizumab
16%
Confidence Intervals
15%
Circulating Tumor DNA
14%
cabozantinib
14%
lenvatinib
14%
Recurrence
13%
130-nm albumin-bound paclitaxel
13%
pasireotide
13%
Colonic Neoplasms
13%
Pharmacokinetics
13%
Bevacizumab
12%
ErbB Receptors
12%
Neuroendocrine Tumors
12%
Liver Neoplasms
12%
Biliary Tract
12%
Elderly
11%
Incidence
10%
Clinical Trials, Phase I
10%
Biomarkers
9%
ensituximab
9%
Irinotecan
9%
CC-223
9%
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
9%
Liver
9%